Abstract

This is the third competing renewal application for the Comprehensive Cancer of Wake Forest Community Clinical Oncology Program Research Base (WF Research Base), which was initially funded in 1999.
Specific Aims for the next five years include the following:
Specific Aim 1 : To conduct cancer control studies that impact community oncology practice by enhancing patients'quality of life through prevention and treatment of symptoms across the survivorship lifespan (i.e., from diagnosis to the end of therapy and from the end of therapy forward) in the following thematic areas: botanical/natural products and other integrative approaches;conventional pharmacologic agents;behavioral interventions;non-intervention studies (e.g., correlative science and observational/longitudinal studies;and cancer prevention trials).
Specific Aim 2 : To use correlative science in conjunction with WF Research Base cancer control studies to understand the basic mechanisms by which symptoms and toxicities of cancer and its treatments occur.
Specific Aim 3 : To develop and utilize innovative, culturally-tailored strategies to increase the participation of racial/ethnic minorities traditionaly underrepresented in cancer control studies.
Specific Aim 4 : To foster active collaboration and offer training in the development, conduct, and reporting of cancer control clinical trials for CCOP/MBCCOP professionals, early career faculty, and trainees. The current application is the strongest competing renewal application for the WF Research Base in our 12 year history. Over time, we have increased the number of studies, accruals, and affiliated communities and institutions. The diversity, depth and breadth of our four open and four soon-to-open studies and 20 developing concepts is evidence of the unique and diverse menu of studies we provide, and the important niche we fill for our participating CCOPs, MBCCOPs and Prevention Members.

Public Health Relevance

The Wake Forest CCOP Research Base conducts cancer control studies that impact community practice utilizing botanical/natural products, other integrative approaches, conventional pharmacologic agents, and behavioral interventions. Our goal is to enhance patients'quality of life through prevention and treatment of symptoms across the survivorship lifespan (i.e., from diagnosis to the end of therapy forward).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA081851-13
Application #
8520190
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Brell, Joanna M
Project Start
1999-09-07
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
13
Fiscal Year
2013
Total Cost
$2,606,423
Indirect Cost
$859,427

  Institution

Name
Wake Forest University Health Sciences
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157

  Publications

Datta, Mridul; Shaw, Edward G; Lesser, Glenn J et al. (2018) A Randomized Double-Blind Placebo-Controlled Trial of Fruit and Vegetable Concentrates on Intermediate Biomarkers in Head and Neck Cancer. Integr Cancer Ther 17:115-123
Lawrence, J A; Griffin, L; Balcueva, E P et al. (2016) A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv 10:176-84
Minasian, Lori M; Tangen, Catherine M; Wickerham, D Lawrence (2015) Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol 42:748-63
Greven, Kathryn M; Case, L Douglas; Nycum, Lawrence R et al. (2015) Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106. J Community Support Oncol 13:87-94
Rapp, Stephen R; Case, L Doug; Peiffer, Ann et al. (2015) Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. J Clin Oncol 33:1653-9
Peiffer, Ann M; Leyrer, C Marc; Greene-Schloesser, Dana M et al. (2013) Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline. Neurology 80:747-53
Spigel, David R; Ervin, Thomas J; Ramlau, Rodryg A et al. (2013) Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31:4105-14
O'Flaherty, Joseph T; Wooten, Rhonda E; Samuel, Michael P et al. (2013) Fatty acid metabolites in rapidly proliferating breast cancer. PLoS One 8:e63076
Vitolins, Mara Z; Griffin, Leah; Tomlinson, W Vic et al. (2013) Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. J Clin Oncol 31:4092-8
Lesser, Glenn J; Case, Doug; Stark, Nancy et al. (2013) A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol 11:31-42

Showing the most recent 10 out of 25 publications